Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. / Deacon, Carolyn F.
In: Current Opinion in Investigational Drugs, Vol. 9, No. 4, 2008, p. 402-13.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
AU - Deacon, Carolyn F
N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil
PY - 2008
Y1 - 2008
N2 - Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
AB - Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
M3 - Journal article
C2 - 18393107
VL - 9
SP - 402
EP - 413
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 4
ER -
ID: 8416764